O

Open Orphan PLC
LSE:ORPH

Watchlist Manager
Open Orphan PLC
LSE:ORPH
Watchlist
Price: 10 GBX 5.26% Market Closed
Market Cap: 67.1m GBX

Net Margin
Open Orphan PLC

-1.6%
Current
-18%
Average
1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.6%
=
Net Income
-776k
/
Revenue
48.5m

Net Margin Across Competitors

No Stocks Found

Open Orphan PLC
Glance View

Open Orphan Plc provides pharmaceutical development services. The firm is engaged in the testing of vaccines and antivirals using human clinical trials. The firm has a presence in the United Kingdom, Ireland, France and Netherlands. The Company, through its subsidiary hVIVO Limited, is also engaged in the data platform business. hVIVO Limited has built up databases of infectious disease progression data and the Company is populating its Open Orphan Health Data platform with hVIVO data. The firm also operates through its subsidiary Venn Life Sciences, which is an integrated drug development partner. Venn Life Sciences offers a combination of drug development consultancy, clinical trial design and execution to create, plan and execute drug development programs for its customers.

ORPH Intrinsic Value
Not Available
O
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.6%
=
Net Income
-776k
/
Revenue
48.5m
What is the Net Margin of Open Orphan PLC?

Based on Open Orphan PLC's most recent financial statements, the company has Net Margin of -1.6%.

Back to Top